Wuyi Intl Pharmaceutical : Voluntary Announcement Business Update

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WUYI INTERNATIONAL PHARMACEUTICAL COMPANY LIMITED

武夷國際藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1889)

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE

This voluntary announcement is made by Wuyi International Pharmaceutical Company Limited (the "Company", together with its subsidiaries, the "Group") to keep the shareholders of the Company and potential investors informed of the latest business development of the Group.

The board of directors (the "Board") of the Company is pleased to announce that the Company is currently exploring suitable opportunities to commence and develop business (the "New Potential Business") of provision of financial leasing services in the People's Republic of China (the "PRC"). The Board intends to develop the New Potential Business through self-development of the subsidiaries and establishing a management team equipped with related knowledge and experience internally.

The Board has been actively exploring other business opportunities in order to diversify the existing business of the Group and to explore new markets with significant growth potential. In view of the current economic and capital markets environment in the PRC, the Board believes that engaging in the New Potential Business is an opportunity of the Group to diversify its source of income and will therefore be in the interest of the Company and our shareholders as a whole.

Notwithstanding the Group's intention to explore the New Potential Business, the existing principal business of the Group in the development, manufacturing, marketing and sales of pharmaceutical products, will continue to be the core business of the Group. If the New Potential Business materializes, we will comply with the applicable requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited by making the necessary announcement and where required, seeking our shareholders' approval.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares in the Company.

By Order of the Board

Wuyi International Pharmaceutical Company Limited Lin Ou Wen

Chairman and Chief Executive Officer

Hong Kong, 5 January 2017

As at the date of this announcement, the Board comprises 2 Executive Directors, namely, Mr. Lin Ou Wen (Chairman) and Mr. Lin Min, and 3 Independent Non-executive Directors, namely, Mr. Zhang Jie, Mr. Zhang Xue Wen and Mr. Wu Cheng Han.